Tg Therapeutics (TGTX) Change in Accured Expenses (2011 - 2026)

Tg Therapeutics' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $34.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 47.81% year-over-year to $34.0 million in Q1 2026; TTM through Mar 2026 was -$33.5 million, a 170.18% decrease from a year earlier, with the FY2025 full-year figure at -$2.4 million, down 110.43% from the prior year.
• Change in Accured Expenses advanced to $34.0 million in Q1 2026 per TGTX's latest filing, from $266000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $65.2 million in Q1 2025 and bottomed at -$67.5 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $2.4 million (2022), against an average of $3.5 million.
• Across the five-year window, Change in Accured Expenses plunged 1905.92% in 2022 and soared 6397.9% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $874000.0 in 2022, then jumped by 477.46% to $5.0 million in 2023, then surged by 296.02% to $20.0 million in 2024, then tumbled by 98.67% to $266000.0 in 2025, then jumped by 12687.97% to $34.0 million in 2026.
• Per Business Quant, the three latest TGTX Change in Accured Expenses figures stand at $34.0 million (Q1 2026), $266000.0 (Q4 2025), and -$277000.0 (Q3 2025).